Betta Pharmaceuticals Co., Ltd.

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
37.74 ^CNY	+0.21%		-5.70%	-26.79%

04-19	Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
01-04	C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	CI

Betta Pharmaceuticals Co Ltd Appoints Fan Jianxun as CFO

April 07, 2017 at 11:30 am

Betta Pharmaceuticals Co Ltd. has appointed Fan Jianxun as chief financial officer of the company.

Latest news about Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-19	CI
C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	01-03	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	25/08/23	CI
Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.	31/07/23	CI
C4 Therapeutics Shares Up 18% After Lung Cancer Drug Application Receives FDA Clearance	05/07/23	DJ
Betta Pharmaceuticals Gets Nod for Voronib Tablets' Listing	09/06/23	MT
C4 Therapeutics, Betta Pharmaceuticals Sign Deal to Develop, Commercialize CFT8919 in Greater China	30/05/23	MT
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC	30/05/23	CI
C4 Therapeutics, Inc. announced that it expects to receive $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.	29/05/23	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/04/23	CI
Betta Pharmaceuticals Gets Nod to Start Clinical Trial of Tumor Drug in China	14/03/23	MT
Betta Pharmaceuticals Co., Ltd. cancelled the transaction announced on June 13, 2022	09/01/23	CI
Betta Pharmaceuticals Co., Ltd. Approves Board Elections	28/12/22	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
Betta Pharmaceuticals Co., Ltd. announced that it expects to receive CNY 999.999991 million in funding	12/06/22	CI
EyePoint Pharmaceuticals Grants Betta Pharmaceuticals Rights to Commercialize Chronic Eye Disorder Treatment in China	04/05/22	MT
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/04/22	CI
Zhejiang Shimai Pharmaceutical Co., Ltd. announced that it has received CNY 30 million in funding from Betta Pharmaceuticals Co., Ltd.	24/04/22	CI
Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	06/04/22	CI
Wuhan Healthgen Biotechnology Corp. announced that it has received CNY 464.999997 million in funding from Hangzhou Beijia Investment Management Co., Ltd., Betta Pharmaceuticals Co., Ltd.	03/04/22	CI
Wuhan Healthgen Biotechnology Corp. announced that it expects to receive CNY 464.999997 million in funding from Hangzhou Beijia Investment Management Co., Ltd., Betta Pharmaceuticals Co., Ltd.	03/03/22	CI
Zhejiang Shimai Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Betta Pharmaceuticals Co., Ltd.	22/01/22	CI

Chart Betta Pharmaceuticals Co., Ltd.

Duration

Period

More charts

Betta Pharmaceuticals Co Ltd is a company mainly engaged in research, development, production and sales of innovative drugs for the treatment of malignant tumors. The Company's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The Company is also engaged in promotional services, real estate leasing and other businesses.

Sector

Pharmaceuticals

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

37.74 CNY

Average target price

50.98 CNY

Spread / Average Target

+35.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
BETTA PHARMACEUTICALS CO., LTD.	-26.79%	2.18B
MERCK KGAA	+16.34%	79.03B
KYOWA KIRIN CO. LTD.	+8.65%	8.78B
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.83B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.22%	4.65B
YUHAN CORPORATION	+2.18%	3.89B
INDIVIOR PLC	+20.51%	2.34B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.12%	2.11B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.56%	2B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals